2024

• Pudipeddi, A., Corte, C., Ward, M., De Cruz, P., Lan-San Fung, C., Redmond, D., Chan, W., Mourad, F., Kermeen, M., Leong, R., Paramsothy, S., et al (2024). Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. [More Information]
• Chetwood, J., Tran, Y., Subramanian, S., Smith, P., Iborra, M., Buisson, A., Paramsothy, S., Leong, R. (2024). Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 18(9), 1440-1449. [More Information]
• Luu, L., Pandey, A., Paramsothy, S., Ngo, C., Castaño-Rodríguez, N., Liu, C., Kamm, M., Borody, T., Man, S., Kaakoush, N. (2024). Profiling the colonic mucosal response to fecal microbiota transplantation identifies a role for GBP5 in colitis in humans and mice. Nature Communications, 15(1). [More Information]

2023

• Anderson, E., Waller, K., Tamilarasan, A., Lin, H., Paramsothy, S., Leong, R. (2023). Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia. Expert Opinion on Biological Therapy. [More Information]
• Pudipeddi, A., Fung, C., Christensen, B., Bryant, R., Subramaniam, K., Chetwood, J., Paramsothy, S., Leong, R. (2023). Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists. World Journal of Gastroenterology, 29(2), 378-389. [More Information]
• Haifer, C., Luu, L., Paramsothy, S., Borody, T., Leong, R., Kaakoush, N. (2023). Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut, 72(1), 90-100. [More Information]
• Lopetuso, L., Deleu, S., Godny, L., Petito, V., Puca, P., Facciotti, F., Sokol, H., Ianiro, G., Masucci, L., Abreu, M., et al (2023). The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut, 72(9), 1642-1650. [More Information]
• Chetwood, J., Leong, R., Gupta, S., Subramaniam, K., De Cruz, P., Moore, G., An, Y., Connor, S., Kermeen, M., Paramsothy, S. (2023). Ustekinumab as induction and maintenance therapy for ulcerative colitis–national extended follow-up and a review of the literature. Expert Opinion on Drug Safety. [More Information]

2022

• Waller, K., Leong, R., Paramsothy, S. (2022). An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. Journal of Gastroenterology and Hepatology, 37(2), 246-255. [More Information]
• Pudipeddi, A., Paramsothy, S., Leong, R. (2022). Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence? Clinical Gastroenterology and Hepatology, 20(3), e640-e641. [More Information]
• Gu, B., Williams, A., Ng, W., Xuan, W., Connor, S., Gholamrezaei, A., Corte, C., Venkatesh, K., Ghaly, S., Paramsothy, S. (2022). Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease. World Journal of Gastroenterology, 28(23), 2597-2608. [More Information]
• Podlesny, D., Durdevic, M., Paramsothy, S., Kaakoush, N., Högenauer, C., Gorkiewicz, G., Walter, J., Fricke, W. (2022). Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Reports Medicine, 3(8). [More Information]
• Haifer, C., Paramsothy, S., Kaakoush, N., Saikal, A., Ghaly, S., Yang, T., Luu, L., Borody, T., Leong, R. (2022). Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology, 7(2), 141-151. [More Information]
• Haifer, C., Paramsothy, S., Kaakoush, N., Leong, R. (2022). Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply. The Lancet Gastroenterology & Hepatology, 7(4), 286-287. [More Information]
• Tamilarasan, A., Tran, Y., Paramsothy, S., Leong, R. (2022). The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology, 37(12), 2207-2216. [More Information]
• Bustamante, S., Yau, Y., Boys, V., Chang, J., Paramsothy, S., Pudipeddi, A., Leong, R., Wasinger, V. (2022). Tryptophan Metabolism ‘Hub’ Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel Disease. International Journal of Molecular Sciences, 23(23). [More Information]
• Pudipeddi, A., Ko, Y., Paramsothy, S., Leong, R. (2022). Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therapeutic Advances in Gastroenterology, 15, 1.76E+16. [More Information]

2021

• Laube, R., Tran, Y., Paramsothy, S., Leong, R. (2021). Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 116(12), 2334-2344. [More Information]
• Williams, A., Paramsothy, R., Wu, N., Ghaly, S., Leach, S., Paramsothy, S., Corte, C., O'Brien, C., Burke, C., Wark, G., et al (2021). Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open, 11(2), e042493. [More Information]
• Kariyawasam, V., Mourad, F., Mitrev, N., Paramsothy, S., Selinger, C., Katelaris, P., Jones, B., McDonald, C., Barr, G., Chapman, G., et al (2021). Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 33(12), 1524-1532. [More Information]
• Pudipeddi, A., Liu, J., Kariyawasam, V., Borody, T., Cowlishaw, J., McDonald, C., Katelaris, P., Chapman, G., Corte, C., Lemberg, D., et al (2021). High prevalence of Crohn disease and ulcerative colitis among older people in Sydney. Medical Journal of Australia, 214(8), 365-370. [More Information]
• Haifer, C., Paramsothy, S., Borody, T., Clancy, A., Leong, R., Kaakoush, N. (2021). Long-term bacterial and fungal dynamics following oral lyophilized fecal microbiota transplantation in clostridioides difficile infection. msystems, 6(1), e00905-20. [More Information]
• Haifer, C., Saikal, A., Paramsothy, R., Kaakoush, N., Leong, R., Borody, T., Kamm, M., Paramsothy, S. (2021). Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. Gut, 70(11), 2210-2211. [More Information]
• Laube, R., Leong, R., Paramsothy, S. (2021). Review of pregnancy in Crohn’s disease and ulcerative colitis. Therapeutic Advances in Gastroenterology, 14, 1-18. [More Information]
• Ko, Y., Paramsothy, S., Yau, Y., Leong, R. (2021). Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Alimentary Pharmacology and Therapeutics, 54(3), 292-301. [More Information]
• Paramsothy, S. (2021). Travel risk management. Journal of Gastroenterology and Hepatology, 36 Suppl 1, 32-33. [More Information]
• Laube, R., Paramsothy, S., Leong, R. (2021). Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opinion on Drug Safety, 20(3), 275-292. [More Information]

2020

• Haifer, C., Kelly, C., Paramsothy, S., Andresen, D., Papanicolas, L., McKew, G., Borody, T., Kamm, M., Costello, S., Andrews, J., van der Poorten, D., Leong, R., et al (2020). Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 69(5), 801-810. [More Information]
• Britton, G., Contijoch, E., Spindler, M., Aggarwala, V., Dogan, B., Bongers, G., Mateo, L., Baltus, A., Das, A., Gevers, D., Paramsothy, S., et al (2020). Defined microbiota transplant restores Th17/ROR gamma t(+) regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proceedings of the National Academy of Sciences of the United States of America, 117(35), 21536-21545. [More Information]
• Leonardi, I., Paramsothy, S., Doron, I., Semon, A., Kaakoush, N., Clemente, J., Faith, J., Borody, T., Mitchell, H., Colombel, J., et al (2020). Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host and Microbe, 27(5), 823-8.29. [More Information]
• Chan, W., Kariyawasam, V., Kim, S., Pudipeddi, A., Paramsothy, S., Shim, H., Mourad, F., Ding, N., Ferrante, M., Leong, R. (2020). Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. European Journal of Gastroenterology and Hepatology, 32, 976-983. [More Information]
• Wasinger, V., Lu, K., Yau, Y., Nash, J., Lee, J., Chang, J., Paramsothy, S., Kaakoush, N., Mitchell, H., Leong, R. (2020). Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for ‘leaky-gut’ in inflammatory bowel disease. Scientific Reports, 10(1), 12932. [More Information]
• Haifer, C., Leong, R., Paramsothy, S. (2020). The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. Current Opinion in Pharmacology, 55, 8-16. [More Information]

2019

• Kayal, M., Saha, A., Poojary, P., Paramsothy, S., Hirten, R., Cohen, L., Gallinger, Z., Mehandru, S., Cho, J., Greenstein, A., et al (2019). Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. International Journal of Colorectal Disease, 34(10), 1771-1779. [More Information]
• Selvaratnam, S., Gullino, S., Shim, L., Lee, E., Lee, A., Paramsothy, S., Leong, R. (2019). Epidemiology of inflammatory bowel disease in South America: A systematic review. World Journal of Gastroenterology, 25(47), 6866-6875. [More Information]
• Pudipeddi, A., Kariyawasam, V., Haifer, C., Baraty, B., Paramsothy, S., Leong, R. (2019). Safety of drugs used for the treatment of Crohn's disease. Expert Opinion on Drug Safety, 18(5), 357-367. [More Information]

2018

• Paramsothy, S., Rosenstein, A., Mehandru, S., Colombel, J. (2018). The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunology, 11(6), 1558-1570. [More Information]

2017

• Paramsothy, S., Paramsothy, R., Rubin, D., Kamm, M., Kaakoush, N., Mitchell, H., Castaño-Rodríguez, N. (2017). Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 11(10), 1180-1199. [More Information]
• Paramsothy, S., Kamm, M., Kaakoush, N., Walsh, A., Van Den Bogaerde, J., Samuel, D., Leong, R., Connor, S., Ng, W., Paramsothy, R., et al (2017). Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet, 389(10075), 1218-1228. [More Information]
• Stier, M., Paramsothy, S., Dalal, S. (2017). Ten-Year Retained Video Capsule With Crohn's-Associated Small-Bowel Adenocarcinoma. Clinical Gastroenterology and Hepatology, 15(10), A29-A30. [More Information]

2016

• Paramsothy, S., Cleveland, N., Zmeter, N., Rubin, D. (2016). The role of biosimilars in inflammatory bowel disease. Gastroenterology & Hepatology, 12(12), 741-751.

2015

• Paramsothy, S., Borody, T., Lin, E., Finlayson, S., Walsh, A., Samuel, D., Van Den Bogaerde, J., Leong, R., Connor, S., Ng, W., et al (2015). Donor recruitment for fecal microbiota transplantation. Inflammatory Bowel Diseases, 21(7), 1600-1606. [More Information]
• Paramsothy, S., Walsh, A., Borody, T., Samuel, D., Van Den Bogaerde, J., Leong, R., Connor, S., Ng, W., Mitchell, H., Kaakoush, N., et al (2015). Gastroenterologist perceptions of faecal microbiota transplantation. World Journal of Gastroenterology, 21(38), 10907-10914. [More Information]

2014

• Borody, T., Brandt, L., Paramsothy, S. (2014). Therapeutic faecal microbiota transplantation: Current status and future developments. Current Opinion in Gastroenterology, 30(1), 97-105. [More Information]

2013

• Borody, T., Brandt, L., Paramsothy, S., Agrawal, G. (2013). Fecal microbiota transplantation: A new standard treatment option for Clostridium difficile infection. Expert Review of Anti-Infective Therapy, 11(5), 447-449. [More Information]
• Borody, T., Paramsothy, S., Agrawal, G. (2013). Fecal microbiota transplantation: Indications, methods, evidence, and future directions. Current Gastroenterology Reports, 15(8). [More Information]